"Benzofurans" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that contain a BENZENE ring fused to a furan ring.
| Descriptor ID |
D001572
|
| MeSH Number(s) |
D03.633.100.127
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzofurans".
Below are MeSH descriptors whose meaning is more specific than "Benzofurans".
This graph shows the total number of publications written about "Benzofurans" by people in this website by year, and whether "Benzofurans" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2017 | 5 | 4 | 9 |
| 2018 | 13 | 6 | 19 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzofurans" by people in Profiles.
-
Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease. Proteins. 2021 11; 89(11):1425-1441.
-
Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI 202012/01): A Computational Study. Mar Drugs. 2021 Apr 25; 19(5).
-
[Salvianolic acid B and its magnesium salt inhibit SARS-CoV-2 infection of Vero-E6 cells by blocking spike protein-mediated membrane fusion]. Nan Fang Yi Ke Da Xue Xue Bao. 2021 Apr 20; 41(4):475-482.
-
Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment. J Comput Chem. 2021 05 15; 42(13):897-907.
-
Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors. Antiviral Res. 2021 05; 189:105055.
-
Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2. J Med Virol. 2021 05; 93(5):3143-3151.
-
The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo. Antiviral Res. 2021 02; 186:105012.
-
Rocaglamide and silvestrol: a long story from anti-tumor to anti-coronavirus compounds. Nat Prod Rep. 2021 01 01; 38(1):18-23.
-
Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol Hepatol. 2019 04; 4(4):269-277.
-
Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. Ann Hepatol. 2019 Jan - Feb; 18(1):236-239.